TGF-beta: a master immune regulator

References

• Lyons RM, Keski-Oja J, Moses HL. Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium. J Cell Biol. 1988 May;106(5):1659–1665.
   PubMed Web of Science ®Google Scholar
• Bai X, Yi M, Jiao Y, et al. Blocking TGF-β signaling to enhance the efficacy of immune checkpoint inhibitor. Oncol Targets Ther. 2019;12:9527–9538.
   PubMed Web of Science ®Google Scholar
• Gupta A, Budhu S, Merghoub T. One checkpoint may hide another: inhibiting the TGFβ signaling pathway enhances immune checkpoint blockade. Hepatobiliary Surg Nutr. 2019 June;8(3):289–294.
   PubMed Web of Science ®Google Scholar
• Haque S, Morris JC. Transforming growth factor-β: a therapeutic target for cancer. Hum Vaccines Immunother. 2017 3;13(8):1741–1750.
   PubMed Web of Science ®Google Scholar
• Hendriks ME, Bolarinwa OA, Nelissen HE, et al. Costs of cardiovascular disease prevention care and scenarios for cost saving: a micro-costing study from rural Nigeria. J Hypertens. 2015;33(2):376–684.
   PubMed Web of Science ®Google Scholar
• Batlle E, Massagué J. Transforming growth factor-β signaling in immunity and cancer. Immunity. 2019 16;50(4):924–940.
   PubMed Web of Science ®Google Scholar
• Yu Y, Feng X-H. TGF-β signaling in cell fate control and cancer. Curr Opin Cell Biol. 2019 Dec;61:56–63.
   PubMed Web of Science ®Google Scholar
• Hatfield SM, Kjaergaard J, Lukashev D, et al. Immunological mechanisms of the antitumor effects of supplemental oxygenation. Sci Transl Med. 2015 Mar 4;7(277):277ra30.
   PubMed Web of Science ®Google Scholar
• Hatfield SM, Kjaergaard J, Lukashev D, et al. Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1α-dependent and extracellular adenosine-mediated tumor protection. J Mol Med Berl Ger. 2014 Dec;92(12):1283–1292.
   PubMed Web of Science ®Google Scholar
• Nagaraj NS, Datta PK. Targeting the transforming growth factor-beta signaling pathway in human cancer. Expert Opin Investig Drugs. 2010 Jan;19(1):77–91.
   PubMed Web of Science ®Google Scholar
• Zhang YE. Non-Smad pathways in TGF-beta signaling. Cell Res. 2009 Jan;19(1):128–139.
   PubMed Web of Science ®Google Scholar
• Massagué J. TGFβ signalling in context. Nat Rev Mol Cell Biol. 2012 Oct;13(10):616–630.
   PubMed Web of Science ®Google Scholar
• Hanyu A, Ishidou Y, Ebisawa T, et al. The N domain of Smad7 is essential for specific inhibition of transforming growth factor-beta signaling. J Cell Biol. 2001 Dec 10;155(6):1017–1027.
   PubMed Web of Science ®Google Scholar
• Huang JJ, Blobe GC. Dichotomous roles of TGF-β in human cancer. Biochem Soc Trans. 2016 15;44(5):1441–1454.
   PubMedGoogle Scholar
• Neel JC, Humbert L, Lebrun JJ. The dual role of TGFβ in human cancer: from tumor suppression to cancer metastasis. ISRN Mol Biol. 2012;2012:381428.
   PubMedGoogle Scholar
• Zhao S, Guo Y, Sheng Q, et al. Advanced heat map and clustering analysis using Heatmap3. BioMed Res Int. 2014;2014:986048.
   PubMedGoogle Scholar
• Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015 Nov;21(11):1350–1356.
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Lorusso D. Immunotherapy and epithelial ovarian cancer: a double-edged sword? Ann Oncol. 2017 May 1;28(5):909–910.
   PubMed Web of Science ®Google Scholar
• Genes [Internet]. [cited 2020 Jan 6]. Available from: https://portal.gdc.cancer.gov/genes/ENSG00000141646
   Google Scholar
• Genes [Internet]. [cited 2020 Jan 6]. Available from: https://portal.gdc.cancer.gov/genes/ENSG00000133703
   Google Scholar
• Saha D, Datta PK, Beauchamp RD. Oncogenic ras represses transforming growth factor-beta/Smad signaling by degrading tumor suppressor Smad4. J Biol Chem. 2001 Aug 3;276(31):29531–29537.
   PubMed Web of Science ®Google Scholar
• Jung B, Gomez J, Chau E, et al. Activin signaling in microsatellite stable colon cancers is disrupted by a combination of genetic and epigenetic mechanisms. Plos One. 2009 Dec 14;4(12):e8308.
   PubMed Web of Science ®Google Scholar
• Heldin CH, Vanlandewijck M, Moustakas A. Regulation of EMT by TGFβ in cancer. FEBS Lett. 2012 July 4;586(14):1959–1970.
   PubMed Web of Science ®Google Scholar
• Donkor MK, Sarkar A, Li MO. Tgf-β1 produced by activated CD4+ T cells antagonizes T cell surveillance of tumor development. Oncoimmunology. 2012 Mar 1;1(2):162–171.
   PubMed Web of Science ®Google Scholar
• Wojtowicz-Praga S. Reversal of tumor-induced immunosuppression by TGF-beta inhibitors. Invest New Drugs. 2003 Feb;21(1):21–32.
   PubMed Web of Science ®Google Scholar
• Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018 23;359(6382):1350–1355.
   PubMed Web of Science ®Google Scholar
• Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019 Nov 15;7(1):306.
   PubMed Web of Science ®Google Scholar
• Schmidt EV, Chisamore MJ, Chaney MF, et al. Assessment of clinical activity of PD-1 checkpoint inhibitor combination therapies reported in clinical trials. JAMA Network Open. 2020 Feb 5;3(2):e1920833.
   PubMed Web of Science ®Google Scholar
• Kumar V, Chaudhary N, Garg M, et al. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol. 2017;8:49.
   PubMed Web of Science ®Google Scholar
• Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018 Dec 1;4(12):1721–1728.
   PubMed Web of Science ®Google Scholar
• Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015 Dec;26(12):2375–2391.
   PubMed Web of Science ®Google Scholar
• Kato S, Goodman A, Walavalkar V, et al. Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res. 2017 Aug 1;23(15):4242–4250.
   PubMed Web of Science ®Google Scholar
• Frelaut M, Le Tourneau C, Borcoman E. Hyperprogression under Immunotherapy. Int J Mol Sci. 2019 May 30;20(11):2674.
   Web of Science ®Google Scholar
• Champiat S, Dercle L, Ammari S, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res. 2017 15; 23(8): 1920–1928.
   PubMed Web of Science ®Google Scholar
• Ferrara R, Mezquita L, Texier M, et al. Hyperprogressive disease in patients with advanced non–small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncol. 2018 Nov;4(11):1543–1552.
   PubMed Web of Science ®Google Scholar
• Kim JY, Lee KH, Kang J, et al. Hyperprogressive disease during Anti-PD-1 (PDCD1)/PD-L1 (CD274) therapy: a systematic review and meta-analysis. Cancers (Basel). 2019 Nov 1;11(11):1699.
   Web of Science ®Google Scholar
• Hugo W, Zaretsky JM, Sun L, et al. Genomic and transcriptomic features of response to Anti-PD-1 therapy in metastatic melanoma. Cell. 2016 Mar 24;165(1):35–44.
   PubMed Web of Science ®Google Scholar
• Mariathasan S, Turley SJ, Nickles D, et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018 22;554(7693):544–548.
   PubMed Web of Science ®Google Scholar
• Tauriello DVF, Palomo-Ponce S, Stork D, et al. TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 2018 22; 554(7693): 538–543.
   PubMed Web of Science ®Google Scholar
• Herbertz S, Sawyer JS, Stauber AJ, et al. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Des Devel Ther. 2015;9:4479–4499.
   PubMed Web of Science ®Google Scholar
• Gulati K, Guhathakurta S, Joshi J, et al. Cytokines and their role in health and disease: a brief overview. MOJ Immunol. 2016;4(2):00121.
   Google Scholar
• Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013 July 25;39(1):1–10.
   PubMed Web of Science ®Google Scholar
• Lan Y, Zhang D, Xu C, et al. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β. Sci Transl Med. 2018 17;10:424.
   Web of Science ®Google Scholar
• David JM, Dominguez C, McCampbell KK, et al. A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells. Oncoimmunology. 2017;6(10):e1349589.
   PubMed Web of Science ®Google Scholar
• Ravi R, Noonan KA, Pham V, et al. Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy. Nat Commun. 2018 Feb 21;9(1):1–14.
   PubMedGoogle Scholar
• Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995 Mar 10;267(5203):1456–1462.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vitale I, Aaronson SA, et al. Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. Cell Death Differ. 2018;25(3):486–541.
   PubMed Web of Science ®Google Scholar
• Reiter I, Krammer B, Schwamberger G. Cutting edge: differential effect of apoptotic versus necrotic tumor cells on macrophage antitumor activities. J Immunol. 1999 Aug 15;163(4):1730–1732.
   PubMed Web of Science ®Google Scholar
• Green DR, Ferguson T, Zitvogel L, et al. Immunogenic and tolerogenic cell death. Nat Rev Immunol. 2009 May;9(5):353.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Buqué A, Kepp O, et al. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17(2):97–111.
   PubMed Web of Science ®Google Scholar
• Schuster N, Krieglstein K. Mechanisms of TGF-beta-mediated apoptosis. Cell Tissue Res. 2002 Jan;307(1):1–14.
   PubMed Web of Science ®Google Scholar
• Kim TA, Kim SJ. Mechanisms of TGF-β-induced apoptosis in cancer cells. In: Jawowlew S, editor. Cancer drug discovery and development: transforming growth factor-beta in cancer therapy: basic and clinical biology. Totowa, NJ: Humana Press Inc; 2008;199-211.
   Google Scholar
• Chen W, Frank ME, Jin W, et al. TGF-beta released by apoptotic T cells contributes to an immunosuppressive milieu. Immunity. 2001 June;14(6):715–725.
   PubMed Web of Science ®Google Scholar
• Huynh M, Fadok VA, Henson PM. Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. J Clin Invest. 2002 Jan;109(1):41–50.
   PubMed Web of Science ®Google Scholar
• Hoffmann PR, Kench JA, Vondracek A, et al. Interaction between phosphatidylserine and the phosphatidylserine receptor inhibits immune responses in vivo. J Immunol. 2005 Feb 1;174(3):1393–1404.
   PubMed Web of Science ®Google Scholar
• Sanjabi S, Oh SA, Li MO. Regulation of the immune response by TGF-β: from conception to autoimmunity and infection. Cold Spring Harb Perspect Biol. 2017 June 1;9(6):a022236.
   PubMed Web of Science ®Google Scholar
• Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18:767–811.
   PubMed Web of Science ®Google Scholar
• Krstic J, Santibanez JF. Transforming growth factor-beta and matrix metalloproteinases: functional interactions in tumor stroma-infiltrating myeloid cells. Sci World J. 2014;2014:521754.
   Web of Science ®Google Scholar
• Esebanmen GE, Langridge WHR. The role of TGF-beta signaling in dendritic cell tolerance. Immunol Res. 2017;65(5):987–994.
   PubMed Web of Science ®Google Scholar
• Dumitriu IE, Dunbar DR, Howie SE, et al. Human dendritic cells produce TGF-beta 1 under the influence of lung carcinoma cells and prime the differentiation of CD4+CD25+Foxp3+ regulatory T cells. J Immunol. 2009 Mar 1;182(5):2795–2807.
   PubMed Web of Science ®Google Scholar
• Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol. 2007 Aug;7(8):610–621.
   PubMed Web of Science ®Google Scholar
• Thepmalee C, Panya A, Junking M, et al. Inhibition of IL-10 and TGF-β receptors on dendritic cells enhances activation of effector T-cells to kill cholangiocarcinoma cells. Hum Vaccines Immunother. 2018 Feb 21;14(6):1423–1431.
   PubMed Web of Science ®Google Scholar
• Ruegemer JJ, Ho SN, Augustine JA, et al. Regulatory effects of transforming growth factor-beta on IL-2- and IL-4-dependent T cell-cycle progression. J Immunol. 1990 Mar 1;144(5):1767–1776.
   PubMed Web of Science ®Google Scholar
• Oh SA, Li MO. TGF-β: guardian of T cell function. J Immunol. 2013 Oct 15;191(8):3973–3979.
   PubMed Web of Science ®Google Scholar
• Chen W, Jin W, Hardegen N, et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med. 2003 Dec 15;198(12):1875–1886.
   PubMed Web of Science ®Google Scholar
• Strauss L, Bergmann C, Szczepanski M, et al. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4345–4354.
   PubMed Web of Science ®Google Scholar
• Hoffman BE, Martino AT, Sack BK, et al. Nonredundant roles of IL-10 and TGF-β in suppression of immune responses to hepatic AAV-factor IX gene transfer. Mol Ther. 2011 July;19(7):1263–1272.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Junca A, Driscoll K, Pellicciotta I, et al. Autocrine TGFβ is a survival factor for monocytes and drives immunosuppressive lineage commitment. Cancer Immunol Res. 2019 Feb;7(2):306–320.
   PubMed Web of Science ®Google Scholar
• Li H, Han Y, Guo Q, et al. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol. 2009 Jan 1;182(1):240–249.
   PubMed Web of Science ®Google Scholar
• Zaiatz-Bittencourt V, Finlay DK, Gardiner CM. Canonical TGF-β signaling pathway represses human NK cell metabolism. J Immunol. 2018 15;200(12):3934–3941.
   PubMed Web of Science ®Google Scholar
• Belladonna ML, Volpi C, Bianchi R, et al. Cutting edge: autocrine TGF-beta sustains default tolerogenesis by IDO-competent dendritic cells. J Immunol. 2008 Oct 15;181(8):5194–5198.
   PubMed Web of Science ®Google Scholar
• Pallotta MT, Orabona C, Volpi C, et al. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol. 2011 July 31;12(9):870–878.
   PubMed Web of Science ®Google Scholar
• Prendergast GC, Smith C, Thomas S, et al. Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. Cancer Immunol. 2014 July;63(7):721–735.
   Google Scholar
• Hanks BA, Holtzhausen A, Evans KS, et al. Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment. J Clin Invest. 2013 Sept;123(9):3925–3940.
   PubMed Web of Science ®Google Scholar
• Bonaventura P, Shekarian T, Alcazer V, et al. Cold tumors: a therapeutic challenge for immunotherapy. Front Immunol. 2019 Feb;8(10):168.
   Google Scholar
• Erdogan B, Webb DJ. Cancer-associated fibroblasts modulate growth factor signaling and extracellular matrix remodeling to regulate tumor metastasis. Biochem Soc Trans. 2017 08;45(1):229–236.
   PubMedGoogle Scholar
• Chakravarthy A, Khan L, Bensler NP, et al. TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure. Nat Commun. 2018 08; 9(1): 4692.
   PubMed Web of Science ®Google Scholar
• Liu T, Han C, Wang S, et al. Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy. J Hematol Oncol. 2019 Aug 28;12(1):86.
   PubMed Web of Science ®Google Scholar
• Ziani L, Chouaib S, Thiery J. Alteration of the antitumor immune response by cancer-associated fibroblasts. Front Immunol. 2018;9:414.
   PubMed Web of Science ®Google Scholar
• Kato T, Noma K, Ohara T, et al. Cancer-associated fibroblasts affect intratumoral CD8+ and FoxP3+ T Cells Via IL6 in the tumor microenvironment. Clin Cancer Res. 2018 01; 24(19): 4820–4833.
   PubMed Web of Science ®Google Scholar
• Monteran L, Erez N. The dark side of fibroblasts: cancer-associated fibroblasts as mediators of immunosuppression in the tumor microenvironment. Front Immunol. 2019;10:1835.
   PubMed Web of Science ®Google Scholar
• Lakins MA, Ghorani E, Munir H, et al. Cancer-associated fibroblasts induce antigen-specific deletion of CD8 + T Cells to protect tumour cells. Nat Commun. 2018 05;9(1):948.
   PubMed Web of Science ®Google Scholar
• Ten Dijke P, Arthur HM. Extracellular control of TGFbeta signalling in vascular development and disease. Nat Rev Mol Cell Biol. 2007 Nov;8(11):857–869.
   PubMed Web of Science ®Google Scholar
• Schaaf MB, Garg AD, Agostinis P. Defining the role of the tumor vasculature in antitumor immunity and immunotherapy. Cell Death Dis. 2018 25;9(2):115.
   PubMed Web of Science ®Google Scholar
• Liu J, Liao S, Diop-Frimpong B, et al. TGF-β blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma. Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):16618–16623.
   PubMed Web of Science ®Google Scholar
• Chauhan VP, Stylianopoulos T, Boucher Y, et al. Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annu Rev Chem Biomol Eng. 2011;2:281–298.
   PubMed Web of Science ®Google Scholar
• Löhr M, Schmidt C, Ringel J, et al. Transforming growth factor-beta1 induces desmoplasia in an experimental model of human pancreatic carcinoma. Cancer Res. 2001 Jan 15;61(2):550–555.
   PubMed Web of Science ®Google Scholar
• Papageorgis P, Stylianopoulos T. Role of TGFβ in regulation of the tumor microenvironment and drug delivery (review). Int J Oncol. 2015 Mar;46(3):933–943.
   PubMed Web of Science ®Google Scholar
• Salmon H, Donnadieu E. Within tumors, interactions between T cells and tumor cells are impeded by the extracellular matrix. Oncoimmunology. 2012 Sept;1(6):992–994.
   PubMed Web of Science ®Google Scholar
• Xu S, Xu H, Wang W, et al. The role of collagen in cancer: from bench to bedside. J Transl Med. 2019 Sept 14;17(1):309.
   PubMed Web of Science ®Google Scholar
• Kuczek DE, Larsen AMH, Thorseth ML, et al. Collagen density regulates the activity of tumor-infiltrating T cells. J Immunother Cancer. 2019 12; 7(1): 68.
   PubMed Web of Science ®Google Scholar
• Topfer K, Kempes S, Muller N, et al. Tumor evasion from T cell surveillance. J Biomed Biotechnol. 2011;2011:918471.
   PubMedGoogle Scholar
• Garrido F, Aptsiauri N, Doorduijn EM, et al. The urgent need to recover MHC class I in cancers for effective immunotherapy. Curr Opin Immunol. 2016 Apr;39:44–51.
   PubMed Web of Science ®Google Scholar
• Ma D, Niederkorn JY. Transforming growth factor-beta down-regulates major histocompatibility complex class I antigen expression and increases the susceptibility of uveal melanoma cells to natural killer cell-mediated cytolysis. Immunology. 1995 Oct;86(2):263–269.
   PubMed Web of Science ®Google Scholar
• Ungefroren H. Blockade of TGF-β signaling: a potential target for cancer immunotherapy? Expert Opin Ther Targets. 2019 Aug;23(8):679–693.
   PubMed Web of Science ®Google Scholar
• Neuzillet C, de Gramont A, Tijeras-Raballand A, et al. Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas. Oncotarget. 2014 Jan 15;5(1):78–94.
   PubMedGoogle Scholar
• Dahmani A, Delisle J-S. TGF-β in T cell biology: implications for cancer immunotherapy. Cancers (Basel). 2018 June 11;10(6):194.
   PubMed Web of Science ®Google Scholar
• Tsubakihara Y, Moustakas A. Epithelial-mesenchymal transition and metastasis under the control of transforming growth factor β. Int J Mol Sci. 2018 Nov 20;19(11):3672.
   Web of Science ®Google Scholar
• Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010 Aug 26;29(34):4741–4751.
   PubMed Web of Science ®Google Scholar
• Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med. 2001 Oct;7(10):1118–1122.
   PubMed Web of Science ®Google Scholar
• Bollard CM, Tripic T, Cruz CR, et al. Tumor-specific T-cells engineered to overcome tumor immune evasion induce clinical responses in patients with relapsed hodgkin lymphoma. J Clin Oncol. 2018 10; 36(11): 1128–1139.
   PubMed Web of Science ®Google Scholar
• Faivre SJ, Santoro A, Gane E, et al. A phase 2 study of galunisertib, a novel transforming growth factor-beta (TGF-β) receptor I kinase inhibitor, in patients with advanced hepatocellular carcinoma (HCC) and low serum alpha fetoprotein (AFP). J Clin Oncol. 2016 May 20;34(15_suppl):4070.
   Web of Science ®Google Scholar
• Rodon J, Carducci MA, Sepulveda-Sánchez JM, et al. First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma. Clin Cancer Res. 2015 Feb 1;21(3):553–560.
   PubMed Web of Science ®Google Scholar
• Gkretsi V, Stylianou A, Papageorgis P, et al. Remodeling components of the tumor microenvironment to enhance cancer therapy. Front Oncol. 2015;5:214.
   PubMed Web of Science ®Google Scholar
• Smith NR, Baker D, Farren M, et al. Tumor stromal architecture can define the intrinsic tumor response to VEGF-targeted therapy. Clin Cancer Res. 2013 Dec 15;19(24):6943–6956.
   PubMed Web of Science ®Google Scholar
• Nakai Y, Isayama H, Ijichi H, et al. Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: GECA1. Cancer Sci. 2012;103(8):1489–1492.
   PubMed Web of Science ®Google Scholar
• Kozono S, Ohuchida K, Eguchi D, et al. Pirfenidone inhibits pancreatic cancer desmoplasia by regulating stellate cells. Cancer Res. 2013 Apr 1;73(7):2345–2356.
   PubMed Web of Science ®Google Scholar
• Stauber AJ, Credille KM, Truex LL, et al. Nonclinical safety evaluation of a transforming growth factor β receptor i kinase inhibitor in fischer 344 rats and beagle dogs. J Clin Pract. 2014;4:3.
   Google Scholar
• Van Laer L, Dietz H, Loeys B. Loeys-Dietz syndrome. Adv Exp Med Biol. 2014;802:95–105.
   PubMed Web of Science ®Google Scholar
• Morris JC, Tan AR, Olencki TE, et al. Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PloS One. 2014;9(3):e90353.
   PubMed Web of Science ®Google Scholar
• Smith AL, Robin TP, Ford HL. Molecular pathways: targeting the TGF-β pathway for cancer therapy. Clin Cancer Res. 2012 Sept 1;18(17):4514–4521.
   PubMed Web of Science ®Google Scholar
• Katz LH, Li Y, Chen J-S, et al. Targeting TGF-β signaling in cancer. Expert Opin Ther Targets. 2013 July;17(7):743–760.
   PubMed Web of Science ®Google Scholar
• Shah AH, Tabayoyong WB, Kimm SY, et al. Reconstitution of lethally irradiated adult mice with dominant negative TGF-beta type II receptor-transduced bone marrow leads to myeloid expansion and inflammatory disease. J Immunol. 2002 Oct 1;169(7):3485–3491.
   PubMed Web of Science ®Google Scholar
• Varricchi G, Marone G, Mercurio V, et al. Immune checkpoint inhibitors and cardiac toxicity: an emerging issue. Curr Med Chem. 2018;25(11):1327–1339.
   PubMed Web of Science ®Google Scholar
• Varricchi G, Galdiero MR, Marone G, et al. Cardiotoxicity of immune checkpoint inhibitors. ESMO Open. 2017;2(4):e000247.
   PubMed Web of Science ®Google Scholar
• Sharma P, Hu-Lieskovan S, Wargo JA, et al. Primary, Adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017 09; 168(4): 707–723.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013 July 11;369(2):122–133.
   PubMed Web of Science ®Google Scholar
• Pierce DF, Gorska AE, Chytil A, et al. Mammary tumor suppression by transforming growth factor beta 1 transgene expression. Proc Natl Acad Sci U S A. 1995 May 9;92(10):4254–4258.
   PubMed Web of Science ®Google Scholar
• Tran DQ. TGF-β: the sword, the wand, and the shield of FOXP3+ regulatory T cells. J Mol Cell Biol. 2012 Feb 1;4(1):29–37.
   PubMed Web of Science ®Google Scholar
• Labriola M, Zhu J, Gupta R, et al. Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2019 May 20;37(15_suppl):e16079–e16079.
   Web of Science ®Google Scholar
• Cheng C, Andrews E, Yan K, et al. An approach for determining and measuring network hierarchy applied to comparing the phosphorylome and the regulome. Genome Biol. 2015;16:63.
   PubMed Web of Science ®Google Scholar
• Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell. 2012 Mar 20;21(3):283–296.
   PubMed Web of Science ®Google Scholar
• Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015 May 21;372(21):2006–2017.
   PubMed Web of Science ®Google Scholar
• The Lancet Oncology null. Immunotherapy: hype and hope. Lancet Oncol. 2018;19(7):845.
   PubMed Web of Science ®Google Scholar
• Principe DR, Park A, Dorman MJ, et al. TGFβ blockade augments PD-1 inhibition to promote T-cell mediated regression of pancreatic cancer. Mol Cancer Ther. 2019 Mar;18(3):613–620.
   PubMed Web of Science ®Google Scholar
• Seliger B. Combinatorial approaches with checkpoint inhibitors to enhance anti-tumor immunity. Front Immunol. 2019;10:999.
   PubMed Web of Science ®Google Scholar
• Sow HS, Ren J, Camps M, et al. Combined inhibition of TGF-β signaling and the PD-L1 immune checkpoint is differentially effective in tumor models. Cells. 2019;8(4):320.
   PubMed Web of Science ®Google Scholar